NasdaqGM:NRIXBiotechs
Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?
Nurix Therapeutics (NRIX) has drawn investor attention after two key events. The company reported a new Phase 3 trial for its BTK degrader bexobrutideg and a separate US$10 million milestone payment from collaborator Sanofi.
See our latest analysis for Nurix Therapeutics.
Against this backdrop, Nurix Therapeutics’ recent clinical milestones and collaboration progress have coincided with strong momentum, with a 30 day share price return of 17.52% and a 1 year total shareholder return of...